Indaptus advances Decoy20 Phase I trial; first patient dosed in multi-dose portion

Indaptus Therapeutics, Inc.

Safety Review Committee reviewed initial Decoy20 clinical data; data to be presented at ASCO 2024.
First patient dosed in multi-dose portion of Phase I trial, evaluating safety of repeat administrations.
Company intends to advance Decoy20 into combination studies with a checkpoint inhibitor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.